Molecular Templates reports Q4 2023 net loss $3.9M; BMS termination, $9.5M placement

Molecular Templates, Inc.

Q4 2023 net loss $3.9M ($0.73/sh) vs $22.0M ($5.87/sh) in Q4 2022; revenue $7.0M vs $2.6M.
Cash $11.5M as of Dec 31, 2023; $9.5M private placement closing extends runway to Q4 2024.
Bristol-Myers Squibb terminates collaboration effective June 13, 2024; MTEM plans cost reductions.
MT-6402 shows confirmed PR (70% reduction) in HNSCC; dose expansion enrolling low PD-L1+ patients.
MT-8421 dose escalation second cohort enrolling; early evidence of Treg depletion and T-cell activation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Molecular Templates, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 29, 2024, Molecular Templates, Inc. (the "Company") announced its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001171843-24-001712

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.